Status:
COMPLETED
Platelet Aggregation During the Shift From Clopidogrel to Ticagrelor
Lead Sponsor:
University Magna Graecia
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Antiplatelet therapy with ticagrelor is currently indicated for treatment of patients presenting with acute coronary syndrome. Such therapy is started with the administration of a loading dose in pati...
Eligibility Criteria
Inclusion
- Acute Coronary Syndrome
- Current dual anti platelet treatment with ASA and Clopidogrel
Exclusion
- No coronary revascularization within the previous six months
- Ongoing therapy with ticagrelor, prasugrel or ticlopidine before enrollment
- No treatment with glycoprotein IIb/IIIa inhibitors within the previous 6 days
- Patients which are known to be no responders to Clopidogrel
- Known neoplastic or autoimmune disease
- Liver cirrhosis
- Severe pulmonary disease
- Known disorder of Haemostasis
- Previous Stroke
- Ongoing pregnancy
- Therapy with any inhibitor of P450 Cytochrome until 15 days before enrollment
- Low platelet count or Hb\<10 g/dl
Key Trial Info
Start Date :
November 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01795820
Start Date
November 1 2012
Last Update
February 21 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Magna Graecia University
Catanzaro, Calabria, Italy, 88100